Search results for "ADENOCARCINOMA"

showing 10 items of 589 documents

Three-dimensional conformal radiotherapy in localized carcinoma of prostate: preliminary reports of toxicity in dose-escalation treatment

2007

Purpose Many studies confirmed the evidence of a dose-response relationship in prostate cancer. Escalation of dose using conventional techniques is however limited by rectal tolerance. IMRT and 3D-CRT have been designed to allow dose escalation while not exceeding rectal tolerance. We evaluated the acute and early late tolerance to surrounding organs upon dose escalation from 70 to 78 Gy in 3D-CRT setting, in order to introduce the IMRT process as a routine practice in prostate cancer treatment. Materials and Methods We compared clinical data from 35 patients with localized adenocarcinoma of the prostate, who received 70 Gy within a traditional reconstructed three-dimensional treatment plan…

Oncologymedicine.medical_specialtyGenitourinary systembusiness.industrymedicine.medical_treatmentRectumGeneral Medicinemedicine.diseaseRadiation therapyProstate cancermedicine.anatomical_structureProstateInternal medicineToxicitymedicineAdenocarcinomaRadiologyRadiation treatment planningbusinessRivista Urologia
researchProduct

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

2021

ABSTRACT Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-…

Oncologymedicine.medical_specialtyLIPI scoreLung Neoplasmsmedicine.medical_treatmentImmunologyThyroid Nuclear Factor 1Adenocarcinoma of Lungmedicine.disease_causeTTF1Internal medicinePD-L1Carcinoma Non-Small-Cell LungmedicineClinical endpointKRASImmunology and AllergyHumansLung cancerImmune Checkpoint InhibitorsRC254-282Retrospective StudiesOriginal Researchbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensprognostic factorsRetrospective cohort studyImmunotherapyRC581-607medicine.diseasePrognosisOncologyCohortbiology.proteinAdenocarcinomaKRASimmunotherapyImmunologic diseases. AllergybusinessAdenocarcinoma lung cancerBiomarkersResearch ArticleOncoimmunology
researchProduct

Analysis of immunosuppressive factors produced by tumorspheres in NSCLC: Prognostic value of galectin-3 in adenocarcinoma

2019

Abstract Background Cancer stem cells (CSCs) are targets poorly recognized by the immune surveillance system given that they induce an immunosuppressive microenvironment. The aim of this work is to study the interactions between CSCs and the immune microenvironment in NSCLC. Methods Tumor cells from 8 resected NSCLC patients and 12 cell lines were established as tumorspheres enriched in CSCs and as monolayers. The gene expression of IL-4, IL-10, IL6, IL8 and LGALS-3 was analyzed by RTqPCR. Results were validated at a protein level by a sensitivity bead-based multiplex immunoassay using the Millipore kit for Luminex 100/200. The prognostic value of these factors in silico was determined in a…

Oncologymedicine.medical_specialtyLungbusiness.industryProportional hazards modelHematologymedicine.diseasemedicine.anatomical_structureOncologyGalectin-3Cancer stem cellInternal medicineGene expressionmedicineAdenocarcinomaInterleukin 8businessSurvival analysisAnnals of Oncology
researchProduct

Resectable and borderline resectable pancreatic ductal adenocarcinoma: Role of the radiologist and oncologist in the era of precision medicine

2021

The incidence and mortality of pancreatic ductal adenocarcinoma are growing over time. The management of patients with pancreatic ductal adenocarcinoma involves a multidisciplinary team, ideally involving experts from surgery, diagnostic imaging, interventional endoscopy, medical oncology, radiation oncology, pathology, geriatric medicine, and palliative care. An adequate staging of pancreatic ductal adenocarcinoma and re-assessment of the tumor after neoadjuvant therapy allows the multidisciplinary team to choose the most appropriate treatment for the patient. This review article discusses advancement in the molecular basis of pancreatic ductal adenocarcinoma, diagnostic tools available fo…

Oncologymedicine.medical_specialtyMedicine (General)Palliative carePancreatic ductal adenocarcinomamagnetic resonance imaging (MRI)business.industrymedicine.medical_treatmentClinical Biochemistrypancreatic ductal adenocarcinomapancreatic neoplasmReviewcomputed tomography (CT)Precision medicineDiagnostic toolsmedicine.diseaseReview articleR5-920Borderline resectableInternal medicinePancreatic cancerMedicineRadiologybusinessNeoadjuvant therapy
researchProduct

2015

Background Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer the diagnostic, prognostic and predictive value of these immunologic factors remains unclear. Method The impact of both factors was evaluated in a study collective of 321 clinically well-annotated patients with non-small lung cancer (NSCLC) using immunohistochemistry. Results PD-1 expression by tumor infiltrating lymphocytes (TILs) was found in 22%, whereas tumor cell associated PD-L1 expression wa…

Oncologymedicine.medical_specialtyMultidisciplinaryTumor-infiltrating lymphocytesbusiness.industrymedicine.diseaseExact testBreast cancerInternal medicineCarcinomamedicineAdjuvant therapyAdenocarcinomabusinessLung cancerSurvival ratePLOS ONE
researchProduct

Identification of gene expression profiles in pancreatic ductal adenocarcinoma. Clinical implications

2013

Oncologymedicine.medical_specialtyPancreatic ductal adenocarcinomaHepatologybusiness.industryEndocrinology Diabetes and MetabolismInternal medicineGene expressionGastroenterologyCancer researchMedicineIdentification (biology)businessPancreatology
researchProduct

Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma

2017

Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal solid tumors. Despite extensive preclinical and clinical research, the prognosis of this disease has not significantly improved, with a 5-year survival rate around 7%. There is an urgent need to better understand the molecular pathology of PDAC in order to improve patient selection for current treatment options and to develop novel therapeutic strategies. The PI3K/AKT/mTOR pathway plays a crucial role in PDAC: activation of Akt is a frequent event and has been correlated to poor prognosis and resistance to chemotherapy. Against this background, effective blockage of Akt signaling can lead to programmed cell death a…

Oncologymedicine.medical_specialtyPancreatic ductal adenocarcinomaPancreatic Adenocarcinoma PI3K/AKT/mTOR gemcitabine survivalbusiness.industryHematologyAkt inhibitorPhospho aktGemcitabineOncologyInternal medicinemedicinebusinessmedicine.drug
researchProduct

Pharmacogenetics of treatments for pancreatic cancer

2019

Introduction: Despite clinical efforts, pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The scarcity of effective therapies can be reflected by the lack of reliable biomarkers to adapt anticancer drugs prescription to tumors’ and patients’ features. Areas covered: Pharmacogenetics should provide the way to select patients who may benefit from a specific therapy that best matches individual and tumor genetic profile, but it has not yet led to gains in outcome. This review describes PDAC pharmacogenetics findings, critically reappraising studies on polymorphisms and -omics profiles correlated to response to gemcitabine, FOLFIRINOX, and nab-paclitaxel combinations, as well as l…

Oncologymedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesFOLFIRINOXToxicology030226 pharmacology & pharmacyvalidated tests and clinical trial03 medical and health sciencesnab-paclitaxel0302 clinical medicinePancreatic cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorAnimalsHumansneoplasmspharmacogenetic studieNab-paclitaxelPharmacologyAntineoplastic Combined Chemotherapy Protocolbusiness.industryAnimalPatient SelectionPharmacogeneticfungigemcitabinePancreatic Neoplasmfood and beveragesGeneral MedicinePancreatic cancermedicine.diseasePrognosisSettore CHIM/08 - Chimica Farmaceuticadigestive system diseasesGemcitabinePancreatic NeoplasmsFOLFIRINOXPharmacogenetics030220 oncology & carcinogenesispromises and pitfalls of pharmacogenetic approachebusinessPharmacogeneticsmedicine.drugCarcinoma Pancreatic DuctalHumanExpert Opinion on Drug Metabolism and Toxicology
researchProduct

Prognostic Impact of Vegfa in Resectable Non-Small-Cell Lung Cancer

2014

ABSTRACT Aim: Angiogenesis is a main process which happens in tumors and that promotes its growth, invasive capacity and metastasis. Host genetic variability within VEGF pathway may affect angiogenic signaling and alter patient's sensitivity to anti-angiogenic therapies and therefore the prognostic. The goal in the present study is to analyze the prognostic value of several SNPs in angiogenic genes and the relative expression of those genes, using a cohort of patients diagnosed with resectable non-small cell lung cancer. Methods: This study included 127 resectable (I-IIIA) NSCLC patients. RNA and DNA extractions from tissues were performed using Trizol®. 20 ng of DNA were used for studies o…

Oncologymedicine.medical_specialtyPathologybusiness.industrySingle-nucleotide polymorphismHematologymedicine.diseaseMetastasisVascular endothelial growth factor AOncologyInternal medicineGenotypemedicineTaqManAdenocarcinomabusinessLung cancerSurvival analysisAnnals of Oncology
researchProduct

Prognostic comparison of the pathological classifications of gastric cancer: a population-based study

1998

Aims There is controversy over the value of the pathological classifications of gastric carcinomas in the prediction of patient survival. This study was designed to assess the prognostic value of four widely used pathological classifications, in addition to classical prognostic factors. Methods and results Records from the population-based registry of digestive tract tumours in the department of Cote d'Or (France) have been analysed. All available histopathological slides of gastric cancer resected between 1976 and 1985 were reviewed and classified according to World Health Organization (WHO), Lauren, Ming and Goseki pathological coding systems. A relative survival analysis was performed us…

Oncologymedicine.medical_specialtyPathologyeducation.field_of_studyHistologyMultivariate analysisRelative survivalbusiness.industryStomachPopulationCancerGeneral Medicinemedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureInternal medicinemedicineAdenocarcinomaeducationbusinessPathologicalSurvival rateHistopathology
researchProduct